Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol
- PMID:12152002
- DOI: 10.1067/mcp.2002.125559
Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol
Abstract
Objective: A 7-day triple therapy with lansoprazole, amoxicillin (INN, amoxicilline), and clarithromycin is widely used for eradication of Helicobacter pylori. Because clarithromycin is a potent inhibitor of cytochrome P450 (CYP) 3A, we investigated whether the standard triple therapy with clarithromycin would elicit clinically relevant CYP3A inhibition and alter CYP3A-mediated lansoprazole disposition in H pylori-positive patients.
Methods: Twenty H pylori-positive patients with peptic ulcer disease were randomly assigned to 2 groups: One group received 200 mg clarithromycin, 30 mg lansoprazole, and 750 mg amoxicillin at 8 am and 8 pm for 7 days; the other group received 400 mg clarithromycin, 30 mg lansoprazole, and 750 mg amoxicillin at 8 am and 8 pm for 7 days. Ten healthy control subjects received 30 mg lansoprazole and 750 mg amoxicillin at 8 am and 8 pm for 7 days but did not receive clarithromycin. Urine samples were collected for 3 hours (from 8 am to 11 am) for urinary 6beta-hydroxycortisol and cortisol assay, and midpoint (at 9:30 am) plasma samples for cortisol assay were obtained from all participants before the drug therapy (day 0) and on day 7. In vivo CYP3A activity was assessed by the partial cortisol clearance by means of the formation of 6beta-hydroxycortisol (CL(cortisol-->6beta-hydroxycortisol)) and the urinary 6beta-hydroxycortisol/cortisol ratio. Additional plasma samples for lansoprazole, 5-hydroxylansoprazole, and lansoprazole sulfone assay were obtained at 11 am on day 7.
Results: The groups of patients given 400 and 800 mg/day clarithromycin for H pylori eradication therapy showed 39% (from 2.20 +/- 1.29 to 1.35 +/- 0.88 mL/min [day 0 versus 7, mean +/- SD]; P <.05) and 68% (2.40 +/- 1.22 to 0.76 +/- 0.51 mL/min; P <.05) reductions in CL(cortisol-->6beta-hydroxycortisol), respectively. In contrast, the control subjects given lansoprazole and amoxicillin without clarithromycin showed no significant changes in CL(cortisol-->6beta-hydroxycortisol). The urinary 6beta-hydroxycortisol/cortisol ratio also decreased significantly (P <.05) in the patient groups but not in the control subjects. The mean 3-hour plasma lansoprazole levels elevated in proportion to the doses of clarithromycin: 385 +/- 338 ng/mL for the control subjects, 696 +/- 797 ng/mL for the H pylori-positive patients given 400 mg/day clarithromycin, and 947 +/- 806 ng/mL for the H pylori-positive patients given 800 mg/day clarithromycin (P <.05 versus the control subjects). No significant differences were observed among the groups in the mean plasma ratios of 5-hydroxylansoprazole or lansoprazole sulfone to lansoprazole.
Conclusions: The 7-day H pylori eradication therapy with clarithromycin, amoxicillin, and lansoprazole may elicit substantial inhibition of in vivo CYP3A activity. Although resultant elevations in plasma lansoprazole concentrations may be beneficial for H pylori eradication, caution must be exercised for possible drug interaction with a concomitantly administered CYP3A substrate (s) in patients undergoing H pylori eradication therapy with clarithromycin, amoxicillin, and lansoprazole.
Similar articles
- Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens.Schwartz H, Krause R, Sahba B, Haber M, Weissfeld A, Rose P, Siepman N, Freston J.Schwartz H, et al.Am J Gastroenterol. 1998 Apr;93(4):584-90. doi: 10.1111/j.1572-0241.1998.169_b.x.Am J Gastroenterol. 1998.PMID:9576452Clinical Trial.
- [Comparative effect of lansoprazole/amoxicillin with omeprazole/amoxicillin for the eradication of Helicobacter pylori in patients with duodenal ulcer].Kayser S, Flury R, Zbinden R, Fried M, Wirth HP.Kayser S, et al.Schweiz Med Wochenschr. 1997 Apr 26;127(17):722-7.Schweiz Med Wochenschr. 1997.PMID:9221483Clinical Trial.German.
- Can lansoprazole, amoxicillin, and clarithromycin combination still be used as a first-line therapy for eradication of helicobacter pylori?Güliter S, Keleş H, Ozkurt ZN, Cengiz DU, Kolukisa E.Güliter S, et al.Turk J Gastroenterol. 2005 Mar;16(1):29-33.Turk J Gastroenterol. 2005.PMID:16252185
- [Lansoprazole: a review of its role in Helicobacter pylori eradication therapy].Gisbert JP.Gisbert JP.Rev Esp Enferm Dig. 1999 Feb;91(2):133-43.Rev Esp Enferm Dig. 1999.PMID:10231305Review.Spanish.
- [Eradication rate and side effect from a point of view of Helicobacter pylori eradication of peptic ulcer disease in dual therapy or new triple therapy].Iwasaki A.Iwasaki A.Nihon Rinsho. 1999 Jan;57(1):127-33.Nihon Rinsho. 1999.PMID:10036949Review.Japanese.
Cited by
- Modeling the autoinhibition of clarithromycin metabolism during repeated oral administration.Abduljalil K, Kinzig M, Bulitta J, Horkovics-Kovats S, Sörgel F, Rodamer M, Fuhr U.Abduljalil K, et al.Antimicrob Agents Chemother. 2009 Jul;53(7):2892-901. doi: 10.1128/AAC.01193-08. Epub 2009 May 4.Antimicrob Agents Chemother. 2009.PMID:19414584Free PMC article.Clinical Trial.
- Helicobacter pylori as a potential target for the treatment of central serous chorioretinopathy.Casella AM, Berbel RF, Bressanim GL, Malaguido MR, Cardillo JA.Casella AM, et al.Clinics (Sao Paulo). 2012 Sep;67(9):1047-52. doi: 10.6061/clinics/2012(09)11.Clinics (Sao Paulo). 2012.PMID:23018302Free PMC article.
- Pharmacokinetics of proton pump inhibitors in children.Litalien C, Théorêt Y, Faure C.Litalien C, et al.Clin Pharmacokinet. 2005;44(5):441-66. doi: 10.2165/00003088-200544050-00001.Clin Pharmacokinet. 2005.PMID:15871633Review.
- Effect of the fluoroquinolone antibacterial agent DX-619 on the apparent formation and renal clearances of 6β-hydroxycortisol, an endogenous probe for CYP3A4 inhibition, in healthy subjects.Imamura Y, Murayama N, Okudaira N, Kurihara A, Inoue K, Yuasa H, Izumi T, Kusuhara H, Sugiyama Y.Imamura Y, et al.Pharm Res. 2013 Feb;30(2):447-57. doi: 10.1007/s11095-012-0890-6. Epub 2012 Oct 17.Pharm Res. 2013.PMID:23073666
- Pharmacokinetic interactions between ilaprazole and clarithromycin following ilaprazole, clarithromycin and amoxicillin triple therapy.Cao S, Zhou G, Ou-Yang DS, Wu HZ, Xiao K, Chen Y, Guo D, Fan L, Tan ZR, Hu HT, Qin XH, Zhou HH, Zhang W.Cao S, et al.Acta Pharmacol Sin. 2012 Aug;33(8):1095-100. doi: 10.1038/aps.2012.64. Epub 2012 Jul 23.Acta Pharmacol Sin. 2012.PMID:22820908Free PMC article.Clinical Trial.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Medical